Physician profile
Randall E Hunt
NPI 1306835756
$1,148.12
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $223 · 2021: $428 · 2022: $322.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $189.98 | 2019-2022 | |
| Abbvie INC. | $185.31 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.18 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.87 | 2019-2022 | |
| Glaxosmithkline, LLC. | $80.93 | 2019-2022 | |
| Novo Nordisk INC | $77.44 | 2019-2022 | |
| Abbott Laboratories | $66.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.93 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.85 | 2021 | |
| Lilly USA, LLC | $40.03 | 2020 | |
| Sunovion Pharmaceuticals INC. | $39.13 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $30.34 | 2020 | |
| Eisai INC. | $28.38 | 2021 | |
| Genentech USA, INC. | $26.06 | 2019-2021 | |
| Astellas Pharma US INC | $24.66 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $20.09 | 2019 | |
| Bardy Diagnostics, INC. | $20.00 | 2021 | |
| Mylan Specialty L.P. | $15.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.08 | 2022 | |
| Kyowa Kirin, INC. | $12.73 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.